Author Archives: Patrick Clinton

Coming Soon: Cancer Wars

By Patrick Clinton | Published: October 15, 2008
What if the industry develops highly effective cancer treatments and no one pays for them? BusinessWeek takes on the question in a reasonably savvy brief article this week. A sample: “At some point—and that point will come sooner rather than later—payers are not going to approve spending $100,000 for someone to live an extra six months,” [...]
Posted in Strategy | Tagged , , | 1 Comment

The Real China Strategy

By Patrick Clinton | Published: August 12, 2008
There’s a lot of talk these days about India and China as potential markets and as sources for cheap manufacturing and R&D. But the real potential of these countries is far more interesting: As China and India (and Brazil, Russia, and Korea) learn to create new products, they’re going to do it at price [...]
Posted in Biotech, Deals, Emerging Markets, Strategy | Tagged , , , , , | 10 Comments

"Side Effects" and "The Normalization of Suspicion"

By Patrick Clinton | Published: July 16, 2008
In today’s Wall Street Journal, Mark Herrmann, an attorney with Jones Day, co-proprietor of the Drug and Device Law blog, as well as an occasional contributor to Pharm Exec, has a lively review of Alison Bass’ Side Effects, a new book that tells the story of the campaign against Paxil. His bottom line is a [...]
Posted in Corporate Responsibility, Safety | Tagged , , , , , , | Leave a comment

Gene Therapy Files for Approval

By Patrick Clinton | Published: July 1, 2008
An estimated one thousand clinical trials have been conducted for gene therapies in the past 20 years, but to date, not a single drug has made it to FDA approval. However, we may be a step closer as Introgen today announced that it has filed applications with FDA and EMEA for marketing approval of Advexin, [...]
Posted in Gene therapy, R&D | Leave a comment

Biotech Watch: Dual Opiates, Certified Pigs

By Patrick Clinton | Published: June 24, 2008
Just back from BIO, where two of the most interesting conversations I had were with companies from Down Under. First was Paul Tan, CEO of Living Cell Technologies, which is officially headquartered in Melbourne Australia, but operates out of Auckland, New Zealand. The company is developing a diabetes therapy that involves implanting specially encapsulated pig pancreas [...]
Posted in Biotech | 1 Comment